For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting

D. Neil Hayes, John Patrick Gleysteen, David Louis Schwartz

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish (US)
Article numberJCO.22.00274
JournalJournal of Clinical Oncology
Volume69
DOIs
StatePublished - Apr 1 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this